Medicilon(SH:688202) Zheng Quan Zhi Xing·2025-07-18 12:11Summary of Key Points Core Viewpoint - The announcement details a share reduction plan by shareholder Lin Changqing of Shanghai Medicy Bio-Pharmaceutical Co., Ltd., due to personal funding needs, involving a maximum reduction of 2,000,000 shares, representing 1.49% of the total share capital [1][2]. Shareholder Holding Situation - As of the announcement date, Lin Changqing holds 5,473,654 shares, accounting for 4.07% of the total share capital, while his associate Chen Guoxing holds a total of 10,348,808 shares, representing 7.70% [1][2]. - The shares were acquired before the company's IPO and through capital reserve conversion [1][2]. Reduction Plan Details - Lin Changqing plans to reduce his holdings through centralized bidding or block trading, with a maximum of 2,000,000 shares to be sold within three months after the disclosure of the reduction plan [1][3]. - The reduction will occur from August 11, 2025, to November 10, 2025, and will be adjusted based on any corporate actions such as dividends or stock splits during the reduction period [2][3]. Future Holding Intentions - After the reduction, Lin Changqing intends to continue holding shares and will comply with relevant laws and commitments regarding further reductions based on personal development needs [2][3]. Compliance and Commitments - Lin Changqing has made commitments regarding the lock-up period and conditions under which he can reduce his holdings, including a prohibition on transferring shares for 36 months post-IPO and specific conditions for further reductions [3][4]. - The company confirms that Lin Changqing does not fall under any restrictions that would prevent him from reducing his shares [5].